Evidence map›Paper›PMID 39899719›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

High-throughput discovery of inhibitory protein fragments with AlphaFold.

Andrew Savinov, Sebastian Swanson, Amy E Keating, Gene-Wei Li

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. BoltzGen: Toward Universal Binder Design.bioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. High-throughput discovery of inhibitory protein fragments with AlphaFold.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Review
  10. Advances in Drug Discovery for Cardiomyocyte Proliferation.Current treatment options in cardiovascular medicine · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Andrew Savinov *Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-0333-3199
Sebastian Swanson *Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
Amy E KeatingDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0003-4074-8980
Gene-Wei LiDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0001-7036-8511

Funding

Evolution and Regulation of Bacterial Proteome CompositionR35GM124732 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Gene-Wei Li · 2017 to 2026
$3.8M
Computational and Experimental Investigation and Design of Protein Interaction SpecificityR35GM149227 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI AMY E KEATING · 2023 to 2026
$2.2M
Cytotoxicity and function of incomplete proteinsK99GM148718 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SAVINOV, ANDREW · 2023 to 2024
$248k
Protein fragments as cotranslationally-acting inhibitorsF32GM134557 · NIGMS · UNIVERSITY OF WASHINGTON · PI SAVINOV, ANDREW · 2020 to 2022
$171k
NIGMS NIH HHS F32 GM134557NIGMS NIH HHS K99 GM148718NIGMS NIH HHS R35 GM124732NIGMS NIH HHS R35 GM149227
6 · The paper itself

Abstract

Peptides can bind to specific sites on larger proteins and thereby function as inhibitors and regulatory elements. Peptide fragments of larger proteins are particularly attractive for achieving these functions due to their inherent potential to form native-like binding interactions. Recently developed experimental approaches allow for high-throughput measurement of protein fragment inhibitory activity in living cells. However, it has thus far not been possible to predict de novo which of the many possible protein fragments bind to protein targets, let alone act as inhibitors. We have developed a computational method, FragFold, that employs AlphaFold to predict protein fragment binding to full-length proteins in a high-throughput manner. Applying FragFold to thousands of fragments tiling across diverse proteins revealed peaks of predicted binding along each protein sequence. Comparisons with experimental measurements establish that our approach is a sensitive predictor of fragment function: Evaluating inhibitory fragments from known protein-protein interaction interfaces, we find 87% are predicted by FragFold to bind in a native-like mode. Across full protein sequences, 68% of FragFold-predicted binding peaks match experimentally measured inhibitory peaks. Deep mutational scanning experiments support the predicted binding modes and uncover superior inhibitory peptides in high throughput. Further, FragFold is able to predict previously unknown protein binding modes, explaining prior genetic and biochemical data. The success rate of FragFold demonstrates that this computational approach should be broadly applicable for discovering inhibitory protein fragments across proteomes.

Indexed as

Computational BiologyHigh-Throughput Screening AssaysPeptide FragmentsProteinsBinding SitesModels, MolecularProtein BindingPeptide FragmentsProteinsdeep mutational scanningFragFoldinhibitory peptidesmassively parallelprotein interactions

Identifiers

PMID39899719
PMCPMC11831152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.